We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > FSD201

News List

First hospitalised COVID-19 patient dosed in FSD201 treatment trial europeanpharmaceuticalreview
December 18, 2020
The study will evaluate whether FSD201 is safe and of benefit to hospitalised patients with COVID-19, in combination with standard of care.
FSD Pharma applies to FDA for trial testing FSD201 in COVID-19 patients europeanpharmaceuticalreview
September 03, 2020
The Investigational New Drug Application (IND) is for a Phase II trial evaluating the safety and efficacy of FSD201 (ultramicronized PEA) in hospitalised COVID-19 patients.
FSD Pharma seeks FDA nod for FSD201 phase 2 trial in Covid-19 patients pharmaceutical-business-review
September 02, 2020
FSD Pharma has filed an application with the US Food and Drug Administration (FDA) seeking its approval to launch a phase 2 trial for FSD201 (ultramicronised palmitoylethanolamide, or ultramicronised PEA) in Covid-19 patients.